Joe Mullings | Surgical Robotics Enters New Competitive Era

Hugo FDA cleared. Another entrant in the U.S. market. The clarity and market stratification will continue.

Choice changes everything. Choice forces new strategies. Choice exposes what assumptions were right and which ones were not.

For two decades, surgical robotics was a single entrant game. They set the market.

One system, one economical model, and until recently, sold against budget.

Not clinical differentiation.

New game. More experience. Less assumptions. More data. Greater differentiation.

With more data comes more validation, more friction, more objections. Early opinions and emotional influences will give way to measurable performance.

Assumptions based on hearsay that once felt solid, give way to real world usage cases.

A new market opportunity and decisions made in full daylight.

• Will it be modularity and flexible deployment?
• Perhaps massive global influence of a strategic?
• Portable category that can be “carried around”?
• Blended laparoscopy and robotics into a hybrid model that lowers both capital and operational barriers?
• ASC or Hospital?
• U.S. or OUS? Where the strategics will start first? In order to get the experience and have less competition?

A new field of play is open and the fight for the old space has moved on.

Getting more data quickly will lead to truer yes’s and truer no’s. Nearly all of the early assumptions in this market will be less correct than we think.

The surgical robotics space is no longer a monologue, it is a marketplace. A global one.

The next five years will reshape everything.